Navigation Links
Max Neeman International ISO 27001:2005 Certified for Information Security Management Systems
Date:1/5/2011

RESEARCH TRIANGLE PARK, N.C., Jan. 5, 2011 /PRNewswire/ -- Max Neeman announces the grant of ISO 27001:2005 certificate; one of only a few Indian CROs to be certified for Information Security.  

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)

This updated certification of the world renowned British Standard for Information Security Management Systems (BS 7799-2:2002) is the standard outlining requirements for an Information Security Management System (ISMS). An ISMS helps in designing; implementing and maintaining a set of processes and systems to manage the risk posed to the information assets of an organization. Thus, helps in achieving the standards of – confidentiality, integrity and availability necessary for information security.

India is the hub of outsourced clinical research and this growth can be impeded by the threat posed to the security of the data generated in the trials. Sponsor companies have been seen to be apprehensive about information security.  

Max Neeman is involved in the development of various novel research molecules and handles crucial information related to the development of these molecules. ISO 27001 certification assures that the systems, processes and controls are rigorous to protect the integrity and confidentiality of information.  The certification helps Max Neeman in assuring the clients on integrity and confidentiality of the data generated in clinical research.  

The ISO 27001:2005 certification Max Neeman has achieved, assures that systems, processes and controls are stringent and sound enough to protect the integrity and confidentiality of information. Max Neeman is in par with all the other global Contract Research Organizations and in meeting global standards.

About Max Neeman International

Max Neeman International is a leading India-based CRO. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 31 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
2. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
3. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
4. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
5. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
6. Transposagen and Cellular Dynamics International Cross-License Technologies for Induced Pluripotent Stem Cells
7. Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 Injection
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at J.P. Morgan Healthcare Conference
9. PAREXEL International to Present at J.P. Morgan Healthcare Conference
10. Bacterin International Holdings to Present at the OneMedForum San Francisco 2011
11. SRI International Completes Integration of Sarnoff Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):